FKBPL | |||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Identifiers | |||||||||||||||||||||||||||||||||||||||||||||||||||
Aliases | FKBPL, DIR1, NG7, WISP39, FKBP4, FK506 binding protein like, FKBP prolyl isomerase like | ||||||||||||||||||||||||||||||||||||||||||||||||||
External IDs | OMIM: 617076; MGI: 1932127; HomoloGene: 10529; GeneCards: FKBPL; OMA: FKBPL - orthologs | ||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Wikidata | |||||||||||||||||||||||||||||||||||||||||||||||||||
|
FK506-binding protein like, also known as FKBPL, is a protein that in humans is encoded by the FKBPL gene. [5]
FKBPL has similarity to the immunophilin protein family, which play a role in immunoregulation and basic cellular processes involving protein folding and trafficking. The encoded protein is thought to have a potential role in the induced radioresistance. Also it appears to have some involvement in the control of the cell cycle. [6]
FKBPL is involved in cellular response to stress. It was first isolated in 1999 and was initially named DIR1. [7] It was later reclassified because of its homology to the FKBP family of proteins and was renamed FKBP-like (FKBPL). A separate study that found it to be involved in the stabilisation of newly synthesised p21 termed it Wisp39. [8]
It is known to interact with Hsp90, glucocorticoid receptor and dynamitin and may play a role in signalling, like other FKBPs. [9]
FKBPL has also been shown to influence estrogen receptor signalling and can have a determinant effect on response to the breast cancer drug tamoxifen. [10]
This article incorporates text from the United States National Library of Medicine, which is in the public domain.
FKBPL | |||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Identifiers | |||||||||||||||||||||||||||||||||||||||||||||||||||
Aliases | FKBPL, DIR1, NG7, WISP39, FKBP4, FK506 binding protein like, FKBP prolyl isomerase like | ||||||||||||||||||||||||||||||||||||||||||||||||||
External IDs | OMIM: 617076; MGI: 1932127; HomoloGene: 10529; GeneCards: FKBPL; OMA: FKBPL - orthologs | ||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Wikidata | |||||||||||||||||||||||||||||||||||||||||||||||||||
|
FK506-binding protein like, also known as FKBPL, is a protein that in humans is encoded by the FKBPL gene. [5]
FKBPL has similarity to the immunophilin protein family, which play a role in immunoregulation and basic cellular processes involving protein folding and trafficking. The encoded protein is thought to have a potential role in the induced radioresistance. Also it appears to have some involvement in the control of the cell cycle. [6]
FKBPL is involved in cellular response to stress. It was first isolated in 1999 and was initially named DIR1. [7] It was later reclassified because of its homology to the FKBP family of proteins and was renamed FKBP-like (FKBPL). A separate study that found it to be involved in the stabilisation of newly synthesised p21 termed it Wisp39. [8]
It is known to interact with Hsp90, glucocorticoid receptor and dynamitin and may play a role in signalling, like other FKBPs. [9]
FKBPL has also been shown to influence estrogen receptor signalling and can have a determinant effect on response to the breast cancer drug tamoxifen. [10]
This article incorporates text from the United States National Library of Medicine, which is in the public domain.